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for Atherosclerotic Disease
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S.D. Anker, J.J.P. Kastelein, J.H. Cornel, P. Pais, D. Pella, J. Genest, R. Cifkova, A. Lorenzatti, T. Forster, Z. Kobalava,
L. Vida‑Simiti, M. Flather, H. Shimokawa, H. Ogawa, M. Dellborg, P.R.F. Rossi, R.P.T. Troquay, P. Libby,
and R.J. Glynn, for the CANTOS Trial Group*

a bs t r ac t
BACKGROUND

Experimental and clinical data suggest that reducing inflammation without affecting lipid
levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of
atherothrombosis has remained unproved.
METHODS

We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal
antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial
compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal
myocardial infarction, nonfatal stroke, or cardiovascular death.
RESULTS

At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein
level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab,
37 percentage points greater in the 150-mg group, and 41 percentage points greater in the
300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline.
At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events
per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group,
3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in
the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg
group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95%
CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The
150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for
statistical significance for the primary end point and the secondary end point that additionally
included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs.
placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31).
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CONCLUSIONS

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with
canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by
Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)
n engl j med 377;12
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A Quick Take
is available at
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C

urrent pharmaceutical interventions that are designed to slow the progression of atherosclerosis focus almost exclusively on reducing plasma levels of cholesterol.
However, clinical and experimental data support
an additional critical role for inflammation in atherothrombosis.1-3 We previously found that downstream biomarkers of inflammation such as highsensitivity C-reactive protein and interleukin-6
are associated with an increased risk of cardiovascular events, independent of the cholesterol
level.4,5 We have also found that statins reduce the
levels of cholesterol and markers of inflammation,6 and in a series of clinical trials we and
others subsequently found that beneficial outcomes
after statin therapy relate to both a reduction in
cholesterol level and inflammation inhibition.7-11
Yet, to date, no evidence has shown that reducing
vascular inflammation in the absence of concomitant lipid lowering reduces the rates of cardiovascular events. As such, the inflammatory hypothesis of atherothrombosis has remained unproved.
Interleukin-1β is a cytokine that is central to
the inflammatory response and that drives the
interleukin-6 signaling pathway. Canakinumab,
a fully human monoclonal antibody targeting
interleukin-1β, has antiinflammatory effects and
has been approved for clinical use in rheumatologic disorders.12,13 In a phase 2 trial involving
patients with diabetes who were at high vascular
risk, we found that interleukin-1β inhibition with
canakinumab markedly reduced plasma levels of
interleukin-6 and high-sensitivity C-reactive protein without lowering the level of low-density
lipoprotein (LDL) cholesterol.14 Thus, we hypothesized that canakinumab could provide a critical
proof-of-concept treatment to test the inflammatory hypothesis of atherothrombosis directly. The
Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), a randomized, doubleblind, placebo-controlled trial involving stable
patients with previous myocardial infarction,
evaluated whether canakinumab could prevent
recurrent vascular events in men and women
who have a persistent proinflammatory response,
defined as a high-sensitivity C-reactive protein
level of 2 mg or more per liter.15

of

m e dic i n e

the full text of this article at NEJM.org, was designed by academic members of the executive
committee with input from physician and statistician employees of the sponsor. The protocol was
approved at participating centers by the responsible institutional review board or ethics committee, as applicable in the 39 countries involved.
An independent data and safety monitoring
committee oversaw the trial. The sponsor was
responsible for data collection. The first author
and an academic statistician at Brigham and
Women’s Hospital had full access to the trial
databases, generated trial analyses, prepared the
first draft of the manuscript, and made the decision to submit the manuscript for publication.
The authors assume responsibility for the accuracy and completeness of the data and analyses
and for the fidelity of the trial to the protocol.
Trial Population

Patients were eligible for enrollment if they had
a history of myocardial infarction and had a
blood level of high-sensitivity C-reactive protein
of 2 mg or more per liter despite the use of aggressive secondary prevention strategies. The trial
excluded from enrollment patients with a history
of chronic or recurrent infection, previous cancer other than basal-cell skin carcinoma, a suspected or known immunocompromised state, a
history or high risk of tuberculosis or disease
related to the human immunodeficiency virus,
or ongoing use of other systemic antiinflammatory treatments. Details of the inclusion and exclusion criteria are provided in Section B in the
Supplementary Appendix, available at NEJM.org.
Randomization

Initially, patients were randomly assigned in a
1:1:1 ratio to receive placebo, canakinumab at a
dose of 150 mg, or canakinumab at a dose of
300 mg. After the enrollment of 741 patients, a
50-mg dose of canakinumab was added at the
request of a regulatory agency, and the randomization ratio was adjusted accordingly; we sought
to achieve a final randomization ratio of 1.5
(placebo group):1:1:1 (Section C in the Supplementary Appendix). All doses of canakinumab
and placebo were administered subcutaneously
once every 3 months; for the 300-mg dose, the
Me thods
regimen was 300 mg every 2 weeks for the first
Trial Design and Oversight
two doses, then once every 3 months. RandomizaThis investigator-driven clinical trial was spon- tion was performed with the use of a centralized
sored by Novartis. The trial protocol, available with computer system, with stratification according
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to the time since the index myocardial infarction
The formal evaluation of significance for indiand according to trial part (before vs. after inclu- vidual doses, with adjustment for multiple comsion of the 50-mg dose group).
parisons, followed a closed testing procedure
(Section C in the Supplementary Appendix). On
End Points
the basis of the closed testing procedure, and
The primary efficacy end point was the first oc- with the use of the prespecified allocation of
currence of nonfatal myocardial infarction, any alpha error, the two-sided P value thresholds for
nonfatal stroke, or cardiovascular death in a statistical significance for the primary end point
time-to-event analysis. The trial had two key were 0.01058 for the test of the 300-mg dose of
secondary efficacy end points. The first key sec- canakinumab versus placebo and 0.02115 for the
ondary end point included the components of tests of the other two doses versus placebo. The
the primary end point as well as hospitalization closed testing procedure also specified that forfor unstable angina that led to urgent revascular- mal significance testing for the key secondary
ization. The second key secondary end point, the end points would be performed for any given
incidence of new-onset type 2 diabetes among dose only if the significance threshold for the
patients with prediabetes at randomization in a primary end point for that dose had been met.
Although the primary analysis strategy was
time-to-event analysis, is not reported here. The
two other prespecified secondary end points were based on pairwise comparisons of individual dose
death from any cause and the composite of non- groups with the placebo group, comparisons
fatal myocardial infarction, any nonfatal stroke, were also made between the incidence rates in
or death from any cause. All the components of the placebo group and the incidence rates across
these end points were adjudicated by an end-point the ascending canakinumab doses (using scores
adjudication committee, whose members were of 0, 1, 3, and 6 that were proportional to doses
in a trend analysis) and in the combined cana
unaware of the trial-group assignments.
kinumab groups versus placebo. In addition,
Statistical Analysis
analyses that focused on patients who adhered
The trial was designed to accrue a total of 1400 to the trial regimen were performed, with followprimary end-point events across all the groups. up for each patient being censored 119 days after
Assuming that all three active doses would re- the last injection was received. The significance
sult in a primary event rate that was 20% lower thresholds for these tests were not adjusted for
than the rate with placebo, we calculated that multiple comparisons. Similar analyses were used
the trial would have more than 90% power to for adverse events. All P values are two-sided,
detect a significantly lower risk with at least one and all confidence intervals were computed at
canakinumab dose than with placebo. The inves- the 95% level.
tigators initially sought to enroll 17,200 patients
in order to accrue 1400 events over a period of
R e sult s
5 years. In December 2013, at the request of the
sponsor, the sample size was reduced to 10,000 Patients
patients. The planned follow-up was extended by Trial enrollment began in April 2011 and was
1 year to maintain the targeted number of events. completed in March 2014; the last trial visit was
The distributions of the percentage change in June 2017. Of 17,482 patients who had previfrom baseline in the high-sensitivity C-reactive ously had myocardial infarction and had underprotein and lipid levels were compared between gone screening in the central laboratory, 10,061
the placebo group and each canakinumab group (57.6%) underwent randomization correctly and
at intervals up to 48 months. Similar comparisons received at least one dose of canakinumab or
were made for interleukin-6 levels up to 12 months. placebo (Fig. S1 in the Supplementary Appendix).
Log-rank tests and Cox proportional-hazards The most common reasons for exclusion were a
models, stratified according to the time since high-sensitivity C-reactive protein level of less
the index myocardial infarction and according than 2 mg per liter (46.0% of the excluded pato trial part, were used to analyze the prespec- tients), active tuberculosis or tuberculosis risk
ified primary and key secondary cardiovascular factors (25.4%), and exclusionary concomitant
end points that occurred during trial follow-up, disorders (9.9%).
according to the intention-to-treat principle.
The mean age of the participants who undern engl j med 377;12
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61.1±10.1
541 (24.9)
531 (24.5)
29.9 (26.6–33.9)
1751 (80.7)
854 (39.4)
1231 (56.7)
710 (32.7)
229 (10.6)
1454 (67.0)
302 (13.9)
451 (20.8)
2038/2169 (94.0)
1990/2169 (91.7)
1718/2166 (79.3)
1974/2169 (91.0)
2059/2169 (94.9)
4.25 (2.80–7.15)
2.53 (1.80–4.17)
159 (136–189)
81.2 (62.3–106.0)
43.7 (37.0–52.2)
140 (102–198)
79.0 (64.0–92.0)
9 (0.4)

1807 (54.0)
1132 (33.9)
405 (12.1)
2192 (65.6)
469 (14.0)
721 (21.6)
3132/3344 (93.7)
3045/3344 (91.1)
2665/3338 (79.8)
3080/3344 (92.1)
3188/3344 (95.3)
4.10 (2.75–6.85)
2.61 (1.80–4.06)
161 (137–190)
82.8 (64.2–107.5)
44.5 (37.1–52.6)
139 (100–194)
79.0 (65.0–93.0)
9 (0.3)

50-mg Group
(N = 2170)

61.1±10.0
865 (25.9)
765 (22.9)
29.7 (26.6–33.8)
2644 (79.1)
1333 (39.9)

Placebo Group
(N = 3344)

1231 (53.9)
781 (34.2)
272 (11.9)
1555 (68.1)†
324 (14.2)
478 (20.9)
2114/2280 (92.7)
2065/2280 (90.6)
1817/2277 (79.8)
2079/2280 (91.2)
2157/2280 (94.6)
4.25 (2.85–7.05)
2.56 (1.74–4.11)
159 (136–188)
82.4 (63.4–106.0)
43.7 (36.3–52.0)†
139 (101–196)
79.0 (64.5–93.0)
5 (0.2)

61.2±10.0
575 (25.2)
534 (23.4)
29.8 (26.5–33.7)
1814 (79.4)
954 (41.8)

61.1±10.1
606 (26.8)
536 (23.7)
29.8 (26.5–33.8)
1799 (79.5)
888 (39.2)

300-mg Group
(N = 2263)

1213 (53.6)
761 (33.6)
289 (12.8)
1509 (66.7)
316 (14.0)
523 (23.1)
2113/2259 (93.5)
2057/2259 (91.1)
1792/2250 (79.6)
2058/2259 (91.1)
2149/2259 (95.1)
4.15 (2.85–7.15)
2.59 (1.79–4.08)
161 (137–189)
83.5 (64.0–108.0)
44.0 (36.7–53.0)
138 (103–194)
78.0 (64.0–93.0)
4 (0.2)

Canakinumab
150-mg Group
(N = 2284)

3675 (54.7)
2252 (33.5)
790 (11.8)
4518 (67.3)
942 (14.0)
1452 (21.6)
6265/6708 (93.4)
6112/6708 (91.1)
5327/6693 (79.6)
6111/6708 (91.1)
6365/6708 (94.9)
4.20 (2.80–7.10)
2.56 (1.77–4.13)
160 (136–189)
82.0 (63.0–106.7)
43.7 (36.7–52.2)†
139 (102–196)
78.5 (64.0–93.0)
18 (0.3)

61.1±10.1
1722 (25.6)
1601 (23.8)
29.9 (26.6–33.8)
5364 (79.9)
2696 (40.1)

All Doses
(N = 6717)

n e w e ng l a n d j o u r na l

n engl j med 377;12

nejm.org

of

*	Plus–minus values are means ±SD. There were no significant between-group differences at baseline, except as noted. The body-mass index is the weight in kilograms divided by the
square of the height in meters. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by
0.01129. CABG denotes coronary-artery bypass grafting, CRP C-reactive protein, GFR glomerular filtration rate, HDL high-density lipoprotein, IQR interquartile range, LDL low-density li
poprotein, PCI percutaneous coronary intervention, and STEMI ST-segment elevation myocardial infarction.
†	P<0.05 for the comparison of canakinumab with placebo.
‡	Anti-ischemia agents were defined as beta-blocking agents, nitrates, or calcium-channel–blocking agents.

Age — yr
Female sex — no. (%)
Current smoking — no. (%)
Median body-mass index (IQR)
Hypertension — no. (%)
Diabetes — no. (%)
Qualifying myocardial infarction — no. (%)
STEMI
Non-STEMI
Unknown type or missing data
History of PCI — no. (%)
History of CABG — no. (%)
History of congestive heart failure — no. (%)
Lipid-lowering therapy — no./total no. (%)
Statin — no./total no. (%)
Renin–angiotensin inhibitor — no./total no. (%)
Anti-ischemia agent — no./total no. (%)‡
Antithrombotic agent or anticoagulant — no./total no. (%)
Median high-sensitivity CRP level (IQR) — mg/liter
Median interleukin-6 level (IQR) — ng/liter
Median total cholesterol level (IQR) — mg/dl
Median LDL cholesterol level (IQR) — mg/dl
Median HDL cholesterol level (IQR) — mg/dl
Median triglyceride level (IQR) — mg/dl
Median estimated GFR (IQR) — ml/min/1.73 m2
Lost to follow-up — no. (%)

Characteristic

Table 1. Characteristics of the Trial Participants.*
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Placebo

Canakinumab,
150 mg

Canakinumab,
300 mg

10
0
−10
−20
−30
−40
−50
−60
−70
0

3

6

9

12

24

36

48

36

48

36

48

36

48

Months

Effects on Inflammatory Biomarkers
and Lipid Levels

Percent Change
from Baseline

B LDL Cholesterol Level

0
−10
0

3

6

9

12

24

Percent Change
from Baseline

C HDL Cholesterol Level
10
0
−10

0

3

6

9

12

24

Months

D Triglyceride Level

Follow-up and Effects on Clinical End Points

By the end of follow-up, 18.1% of patients in the
placebo group had discontinued the trial regimen, as compared with 18.7% of patients in the
combined canakinumab groups (Fig. S1 in the
Supplementary Appendix). At a median follow-up
of 3.7 years, the incidence rate for the primary
end point (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) was 4.50
events per 100 person-years in the placebo group,
4.11 events per 100 person-years in the group
that received the 50-mg dose of canakinumab,
3.86 events per 100 person-years in the 150-mg
group, and 3.90 events per 100 person-years in
the 300-mg group (Table 2). No significant effect,
as compared with placebo, was observed with
regard to the primary end point in the 50-mg

10

Months

Percent Change
from Baseline

At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level
was 26 percentage points greater in the group
that received the 50-mg dose of canakinumab,
37 percentage points greater in the 150-mg group,
and 41 percentage points greater in the 300-mg
group than in the placebo group (P<0.001 for all
comparisons of the median percentage change
in a canakinumab group with the placebo group)
(Fig. 1, and Fig. S2 and Tables S1 through S5 in
the Supplementary Appendix). Similar effects
were observed for the interleukin-6 level (measured up to 12 months). By contrast, canakinumab
use resulted in no significant reduction from
baseline in the LDL cholesterol or HDL cholesterol level and in a 4 to 5% median increase in
the triglyceride level.

n engl j med 377;12

Canakinumab,
50 mg

A High-Sensitivity C-Reactive Protein Level
Percent Change from Baseline

went randomization was 61 years, 25.7% of the
patients were women, and 40.0% had diabetes
(Table 1). Most participants had undergone previous revascularization procedures (66.7% of the
patients had undergone percutaneous coronary
intervention, and 14.0% coronary-artery bypass
grafting). At baseline, antithrombotic agents were
taken by 95.0% of the patients, lipid-lowering
agents by 93.4%, anti-ischemia agents by 91.4%,
and inhibitors of the renin–angiotensin system
by 79.7%. The median high-sensitivity C-reactive
protein level at trial entry was 4.20 mg per liter,
and the median LDL cholesterol level was 82.4 mg
per deciliter (2.13 mmol per liter).

10
0
−10
0

3

6

9

12

24

Months

Figure 1. Effects of Canakinumab, as Compared with Placebo, on Plasma
Levels of High-Sensitivity C-Reactive Protein, Low-Density Lipoprotein (LDL)
Cholesterol, High-Density Lipoprotein (HDL) Cholesterol, and Triglycerides.
Shown are the median percentage changes from baseline (dashed line).
Specific data points, as well as data regarding interleukin-6 levels at 3 months
and 12 months, are presented in Tables S1 through S5 in the Supplementary
Appendix.

group (hazard ratio, 0.93; P = 0.30) (Fig. 2A). By
contrast, a significant effect for the primary end
point was observed in the 150-mg group (hazard
ratio vs. placebo, 0.85; P = 0.02075, with a threshold P value of 0.02115) (Fig. 2B). In the 300-mg
group, the hazard ratio was similar to that in the
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1.00
—

Hazard ratio (95% CI)

P value

Incidence rate per 100 person-yr (no. of patients)

0.74 (92)

—

P value

Any stroke

1.00

3.61 (421)

0.95

1.01 (0.72–1.41)

0.73 (58)

<0.001

0.72 (0.60–0.86)

2.53 (191)

0.07

—

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

Any coronary revascularization

0.48 (38)
0.70 (0.47–1.03)

1.00

1.90 (159)

0.91

0.98 (0.71–1.35)

0.74 (63)

<0.001

0.68 (0.58–0.81)

2.49 (205)

0.02

0.64 (0.44–0.94)

0.44 (38)

0.005

0.76 (0.62–0.92)

0.20

0.80 (0.57–1.13)

0.60 (51)

<0.001

0.70 (0.59–0.83)

2.56 (209)

0.006

0.58 (0.39–0.86)

0.40 (34)

0.07

0.84 (0.70–1.02)

2.09 (174)

0.03

0.87 (0.77–0.99)

4.88 (403)

0.004‖

0.83 (0.72–0.94)

4.25 (348)

0.031‡

0.86 (0.75–0.99)

3.90 (322)

300-mg Group
(N = 2263)

0.58

0.93 (0.72–1.20)

0.69 (172)

<0.001

0.70 (0.62–0.79)

2.53 (605)

0.002

0.64 (0.48–0.85)

0.44 (110)

0.02

0.84 (0.73–0.97)

2.06 (502)

0.01

0.89 (0.81–0.97)

4.93 (1192)

0.001

0.85 (0.77–0.94)

4.36 (1044)

0.02

0.88 (0.79–0.97)

3.95 (955)

All Doses
(N = 6717 )

0.17

<0.001

0.005

0.03

0.02

0.003

0.02

of

Hazard ratio (95% CI)

0.56

0.94 (0.78–1.15)

0.01

0.85 (0.75–0.96)

4.77 (395)

0.005§

0.83 (0.73–0.95)

4.29 (352)

0.021§

0.85 (0.74–0.98)

3.86 (320)

150-mg Group
(N = 2284)

Canakinumab

P Value for Trend
across Doses vs.
Placebo

n e w e ng l a n d j o u r na l

Incidence rate per 100 person-yr (no. of patients)

0.69 (85)

—

P value

Hospitalization for unstable angina that led to urgent
revascularization

1.00

2.20 (169)

0.35

—
2.43 (292)

0.94 (0.83–1.07)

5.17 (394)

0.12‖

0.90 (0.78–1.03)

4.56 (344)

0.30‡

0.93 (0.80–1.07)

4.11 (313)

50-mg Group
(N = 2170)

1.00

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

Myocardial infarction

P value

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

5.56 (661)

—

P value

Myocardial infarction, stroke, or death from any cause

1.00

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

5.13 (601)

—

Key secondary cardiovascular end point¶

1.00

P value

4.50 (535)

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

Primary end point†

Clinical Outcome

Placebo Group
(N = 3344)

Table 2. Incidence Rates and Hazard Ratios for Major Clinical Outcomes and All-Cause Mortality.*
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—

0.48

0.94 (0.80–1.11)
0.33

0.92 (0.78–1.09)

2.73 (238)

0.81

0.97 (0.74–1.26)

1.08 (94)

0.30

0.90 (0.73–1.10)

1.65 (144)

0.30

0.88 (0.70–1.12)

1.26 (110)

150-mg Group
(N = 2284)

0.42

0.94 (0.80–1.10)

2.76 (239)

0.54

0.92 (0.70–1.20)

1.02 (88)

0.59

0.94 (0.77–1.16)

1.74 (151)

0.55

0.93 (0.74–1.18)

1.33 (115)

300-mg Group
(N = 2263)

Canakinumab

0.31

0.94 (0.83–1.06)

2.78 (705)

0.79

0.97 (0.79–1.19)

1.08 (273)

0.28

0.92 (0.78–1.07)

1.70 (432)

0.15

0.87 (0.73–1.05)

1.26 (319)

All Doses
(N = 6717 )

0.39

0.45

0.62

0.76

P Value for Trend
across Doses vs.
Placebo

*	Data are shown as incidence rates per 100 person-years (with numbers of patients with event) to facilitate the comparison of rates between groups. P values for trend, P values for the
combination of all doses as compared with placebo, and P values for all secondary end points other than the key secondary cardiovascular end point have not been adjusted for multi
ple comparisons. CI denotes confidence interval.
†	The primary end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.
‡	This result was not significant as compared with placebo according to the prespecified closed-testing procedure. The threshold P value for the primary end point for the 50-mg dose was
0.02115. The threshold P value for the primary end point for the 300-mg dose was 0.01058.
§	This result was significant as compared with placebo, with adjustment for multiple comparisons and with accounting for two efficacy interim analyses, in accordance with the prespeci
fied closed-testing procedure (Section C in the Supplementary Appendix). The threshold P value for the primary end point for the 150-mg dose was 0.02115. The threshold P value for
the key secondary cardiovascular end point for the 150-mg dose was 0.00529.
¶	The key secondary cardiovascular end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina that led to unplanned revascularization, or cardiovas
cular death.
‖	These analyses were considered to be exploratory.

1.00

Hazard ratio (95% CI)

2.85 (228)

0.87

—
2.97 (375)

1.02 (0.78–1.34)

1.00

1.14 (91)

0.30

—
1.11 (140)

0.89 (0.72–1.11)

1.00

1.71 (137)

0.083

—
1.86 (235)

0.80 (0.62–1.03)

1.18 (94)

50-mg Group
(N = 2170)

1.00

1.44 (182)

P value

Incidence rate per 100 person-yr (no. of patients)

Death from any cause

P value

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

Noncardiovascular death, confirmed

P value

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

Cardiovascular death or death of unknown cause

P value

Hazard ratio (95% CI)

Incidence rate per 100 person-yr (no. of patients)

Cardiovascular death, confirmed

Clinical Outcome

Placebo Group
(N = 3344)
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A Primary End Point with Canakinumab, 50 mg, vs. Placebo
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B Primary End Point with Canakinumab, 150 mg, vs. Placebo

Hazard ratio, 0.93 (95% CI, 0.80–1.07)
P=0.30
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Primary End Point (%)

Cumulative Incidence of
Primary End Point (%)

100

of

5

80

15

60

10

Placebo
Canakinumab, 150 mg

5
40

0

20

0

1

2

3

4

5

10
0

0

1

2

3

4

0

5

0

1

2

Years
No. at Risk
3141
2057

2973
1950

2632
1713

1266
762

210
47

C Primary End Point with Canakinumab, 300 mg, vs. Placebo
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D Key Secondary End Point with Canakinumab, 150 mg, vs. Placebo

Hazard ratio, 0.86 (95% CI, 0.75–0.99)
P=0.031
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Figure 2. Cumulative Incidence of the Primary End Point and the Key Secondary Cardiovascular End Point.
Shown is the cumulative incidence of the primary end point of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death
in the placebo group versus the various canakinumab dose groups (Panels A through C). The insets show the same data on an enlarged
y axis. The threshold P value for the primary end point was 0.02115 in the 150-mg group and 0.01058 in the 300-mg group. The group
receiving the 150-mg dose of canakinumab met the prespecified multiplicity-adjusted threshold for statistical significance for the primary
cardiovascular end point and for the key secondary cardiovascular end point that additionally included hospitalization for unstable angina
that led to urgent revascularization (Panel D). The threshold P value for the key secondary cardiovascular end point in the 150-mg group
was 0.00529.

150-mg group, but the P value did not meet the
prespecified threshold for significance (hazard
ratio vs. placebo, 0.86; P = 0.0314, with a threshold
P value of 0.01058) (Fig. 2C). The P value for
trend across the canakinumab dose groups as
compared with the placebo group was 0.02, and
the P value for the comparison of all canakinumab
doses combined with the placebo group was 0.02
(both results not adjusted for multiple testing).
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For the key secondary cardiovascular end point
(the components of the primary end point plus
hospitalization for unstable angina that led to
urgent revascularization), the incidence rate was
5.13 events per 100 person-years in the placebo
group, 4.56 events per 100 person-years in the
group that received the 50-mg dose of canakinu
mab, 4.29 events per 100 person-years in the
150-mg group, and 4.25 events per 100 person-
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years in the 300-mg group (Table 2). In the group
that received the 150-mg dose of canakinumab
(for which the P value met the significance
threshold for the primary end point), the hazard
ratio versus placebo for the secondary cardiovascular end point was 0.83 (P = 0.00525, with a
threshold P value of 0.00529) (Fig. 2D). According to the closed testing procedure, formal significance testing for the prespecified secondary
end point was not performed for the 50-mg
group and the 300-mg group. The hazard ratio
versus placebo in the 50-mg group was 0.90, and
the hazard ratio versus placebo in the 300-mg
group was 0.83 (Figs. S3 and S4 in the Supplementary Appendix). The P value for trend across
the canakinumab groups as compared with the
placebo group was 0.003, and the P value for the
comparison of all canakinumab doses combined
with the placebo group was 0.001 (both results
not adjusted for multiple testing).
Analyses of the additional secondary end
points and of the components of the primary
and secondary end points were not adjusted for
multiple testing (Table 2). Nominally significant
ly lower rates than in the placebo group were
seen with regard to myocardial infarction in the
group that received the 150-mg dose of canakinu
mab; with regard to hospitalization for unstable
angina that led to urgent revascularization in the
150-mg group and the 300-mg group; and with
regard to any coronary revascularization in all
three dose groups. All-cause mortality was neutral in the comparison of all canakinumab doses
with placebo (hazard ratio, 0.94; 95% confidence
interval, 0.83 to 1.06; P = 0.31).
In analyses that focused on patients who adhered to the trial regimen, the observed hazard
ratios were 1.00 in the placebo group, 0.90 in
the group that received the 50-mg dose of
canakinumab, 0.83 in the 150-mg group, and
0.79 in the 300-mg group (P = 0.003 for trend
across groups). In similar analyses for the key
secondary cardiovascular end point, the corresponding hazard ratios were 1.00, 0.88, 0.80,
and 0.77 (P<0.001 for trend across groups).
Adverse Events and Other Clinical Outcomes

Neutropenia was more common among patients
who were assigned to receive canakinumab than
among those in the placebo group, and significantly more deaths were attributed to infection

n engl j med 377;12

or sepsis in the pooled canakinumab groups
than in the placebo group (incidence rate, 0.31
vs. 0.18 events per 100 person-years; P = 0.02)
(Table 3). The patients who died from infection
tended to be older and more likely to have diabetes than those who did not die from infection.
Six confirmed cases of tuberculosis occurred
during the trial, with similar rates in the pooled
canakinumab group and the placebo group
(0.06% in each group); five cases occurred in
India and one in Taiwan.
Thrombocytopenia was more common among
patients who were assigned to receive canakinu
mab than among those in the placebo group,
but no significant difference in the incidence of
hemorrhage was observed. The incidence rate of
injection-site reaction did not differ significantly
between any canakinumab group and the placebo
group. In a finding that was consistent with
known effects of interleukin-1β inhibition, cana
kinumab resulted in significantly fewer reports
of arthritis, gout, and osteoarthritis than did placebo (Table 3). Cancer mortality was significantly
lower with canakinumab than with placebo.16

Discussion
CANTOS was designed to test directly the inflammatory hypothesis of atherothrombosis. In this
trial, in patients with a history of myocardial
infarction, the levels of high-sensitivity C-reactive protein and interleukin-6 were significantly
reduced from baseline by canakinumab, as compared with placebo, with no significant reduction in lipid levels from baseline. Although the
50-mg dose of canakinumab did not have a significant effect on the primary cardiovascular end
point as compared with placebo, patients in the
150-mg group had a risk of the primary end point
that was 15% lower than the risk in the placebo
group (3.86 vs. 4.50 events per 100 person-years)
and a risk of the key secondary cardiovascular
end point that was 17% lower than that in the
placebo group (4.29 vs. 5.13 events per 100 personyears). The P values for both end points met the
prespecified multiplicity-adjusted thresholds for
statistical significance. Although the hazard ratios
for the comparison of canakinumab with placebo
in the 300-mg group were similar to those in the
150-mg group, the prespecified thresholds for
significance were not met in this group. However,
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11.41 (741)
3.03 (230)
0.24 (19)
0.94 (74)
0.18 (14)
0.16 (13)
0.13 (10)
0.31 (25)
1.85 (144)
0.55 (44)
0.27 (21)
2.15 (164)
1.21 (94)
0.43 (34)
0.15 (12)
0.30 (24)
0.05 (4)
3.33 (249)
0.56 (44)

1.9 (42)
1.5 (32)
0.5 (11)
1.0 (21)

0.23 (29)
3.32 (385)
1.67 (202)
0.80 (99)
0.18 (23)
0.24 (30)
0.06 (7)
4.01 (462)
0.43 (53)

1.4 (46)
1.1 (36)
0.4 (15)
0.8 (26)

50-mg Group
(N = 2170)

11.96 (1202)
2.86 (342)
0.24 (30)
0.90 (112)
0.22 (27)
0.18 (23)
0.03 (4)
0.18 (23)
1.88 (231)
0.64 (81)

Placebo Group
(N = 3344)
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2.0 (45)
1.5 (34)
0.5 (12)
0.7 (15)

0.30 (26)
2.47 (201)
1.30 (109)
0.37 (32)
0.05 (4)
0.52 (44)
0.18 (15)
3.82 (301)
0.71 (60)

12.33 (836)
3.25 (265)
0.41 (35)
0.99 (84)
0.20 (17)
0.20 (17)
0.12 (10)
0.34 (29)
1.72 (144)
0.31 (27)

300-mg Group
(N = 2263)

2.0 (131)
1.5 (101)
0.5 (33)
0.8 (51)

0.28 (71)
2.26 (545)
1.21 (298)
0.38 (96)
0.11 (27)
0.40 (100)
0.10 (25)
3.78 (877)
0.60 (150)

11.82 (2389)
3.14 (753)
0.34 (86)
0.95 (238)
0.21 (52)
0.17 (43)
0.10 (24)
0.31 (78)
1.75 (431)
0.45 (115)

All Doses
(N = 6717)

0.19
0.30
0.67
0.34

0.49
0.002
0.04
<0.001
0.004
0.002
0.01
0.94
0.02

0.43
0.12
0.02
0.56
0.84
0.97
0.13
0.09
0.31
<0.001

For Trend
across Doses
vs. Placebo

0.06
0.11
0.82
0.83

0.36
<0.001
<0.001
<0.001
0.05
0.01
0.17
0.31
0.03

0.79
0.14
0.09
0.62
0.87
0.78
0.03
0.02
0.38
0.02

For Combined
Dose Groups
vs. Placebo

P Value

of

1.9 (44)
1.5 (35)
0.4 (10)
0.7 (15)

0.28 (24)
2.17 (180)
1.12 (95)
0.35 (30)
0.13 (11)
0.37 (32)
0.07 (6)
4.15 (327)
0.54 (46)

11.71 (812)
3.13 (258)
0.37 (32)
0.94 (80)
0.24 (21)
0.15 (13)
0.05 (4)
0.28 (24)
1.69 (143)
0.50 (44)

150-mg Group
(N = 2284)
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*	Data are shown as incidence rates per 100 person-years (with numbers of patients with event) for adverse events and as percentages of patients with the condition (with numbers of pa
tients) for hepatic variables to facilitate the comparison of rates between groups. All adverse-event categories are based on standardized queries or classification levels in the Medical
Dictionary for Regulatory Activities, version 20.0, except those otherwise indicated.
†	These adverse events, including drug-induced liver injury as a serious adverse event, were considered by the sponsor to be adverse events of special interest.
‡	Included here are cancers that were adjudicated by the cancer end-point adjudication committee.

Event — incidence rate per 100 person-yr
(no. of patients with event)
Any serious adverse event
Any serious adverse event of infection
Cellulitis
Pneumonia
Urinary tract infection
Opportunistic infection†
Pseudomembranous colitis
Fatal infection or sepsis
Any cancer‡
Fatal cancer‡
Other adverse event
Injection-site reaction†
Arthritis
Osteoarthritis
Gout
Drug-induced liver injury†
Leukopenia
Neutropenia
Any hemorrhage
Thrombocytopenia
Hepatic variable — percent of patients with
condition (no.)
Alanine aminotransferase >3× normal value
Aspartate aminotransferase >3× normal value
Alkaline phosphatase >3× normal value
Bilirubin >2× normal value

Adverse Event or Laboratory Variable

Table 3. Incidence Rates and Numbers of Serious Adverse Events and Selected Safety Laboratory Data During Treatment, Stratified According to Trial Group.*
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both a pooled analysis of all canakinumab doses
and a trend analysis suggested a beneficial effect
of canakinumab with regard to cardiovascular
outcomes.
The specific targeting of interleukin-1β as a
cytokine-based therapy for the secondary prevention of atherosclerotic events rests on several
observations. The proinflammatory cytokine
interleukin-1β plays multiple roles in the development of atherothrombotic plaque, including
the induction of procoagulant activity, the promotion of monocyte and leukocyte adhesion to
vascular endothelial cells, and the growth of
vascular smooth-muscle cells.17-19 In mice, inter
leukin-1β deficiency reduces lesion formation,
whereas in cholesterol-fed pigs, exposure to exogenous interleukin-1β increases intimal medial
thickening.20,21 The NOD-like receptor protein 3
(NLRP3) inflammasome activates interleukin1β, a process promoted by cholesterol crystals,
neutrophil extracellular traps, tissue hypoxia,
and arterial flow patterns that are known to
promote focal development of atherosclerosis
within arteries.22-25 This activation of interleukin1β stimulates the downstream interleukin-6–
receptor signaling pathway, which has been
implicated by mendelian randomization studies
as a potential causal pathway for atherothrombosis.26,27 More recently, studies in parabiotic
mice28 and studies of clonal hematopoiesis29,30
have implicated interleukin-1β in processes by
which bone marrow activation accelerates atherosclerosis. Furthermore, the expression of specif
ic inflammasome gene modules affecting inter
leukin-1β has been associated with death from
any cause and increased atherosclerosis in elderly
patients.31
Although the patients in CANTOS had generally well-controlled levels of LDL cholesterol, rates
of both the primary end point and the secondary
cardiovascular end point in the placebo group
were high, with cumulative incidences of more
than 20% at 5 years. Our data thus affirm that
statin-treated patients with residual inflammatory
risk as assessed by means of a high-sensitivity
C-reactive protein level of 2 mg or more per liter
at baseline have future event rates that are at
least as high as, if not higher than, those among
statin-treated patients with a residual risk due to
LDL cholesterol level. These two groups of patients may differ and may require personalized

n engl j med 377;12

approaches to treatment.32 Despite the fact that
no significant reduction in cholesterol levels occurred in this trial, the magnitude of effect on
cardiovascular events with canakinumab (given
every 3 months) was similar to that associated
with monoclonal antibodies targeting proprotein
convertase subtilisin–kexin type 9 (PCSK9; given
every 2 to 4 weeks).33,34 Yet, inhibition of inter
leukin-1β is a narrowly focused intervention that
represents only one of many potential anti
inflammatory pathways that might serve as targets for atheroprotection.35-37 Thus, our data suggest that other antiinflammatory interventions,
such as those that directly inhibit NLRP3 function or that alter downstream interleukin-6 signaling, may also be beneficial in reducing cardiovascular risk.
We found a significantly higher incidence of
fatal infection and sepsis with canakinumab than
with placebo, as well as a reduction in platelet
counts with no increase in bleeding risk. By
contrast, cancer mortality was significantly lower among patients assigned to receive canakinumab than among those in the placebo group, a
finding that is consistent with experimental data
relating interleukin-1 to the progression and invasiveness of certain tumors, particularly lung
cancer.16,38,39 There was no significant difference
between the canakinumab groups and the placebo group in all-cause mortality. No statistically or clinically significant hepatic toxic effect
was noted. The beneficial effects of canakinu
mab that were observed with regard to arthritis,
gout, and osteoarthritis are consistent with welldescribed effects of the interleukin-1 and interleukin-6 pathways in these disorders.
In conclusion, in CANTOS, patients with a
history of myocardial infarction and a highsensitivity C-reactive protein level of 2 mg or
more per liter were randomly assigned to one
of three doses of canakinumab or to placebo.
Canakinumab significantly reduced high-sensitivity C-reactive protein levels from baseline, as
compared with placebo, without reducing the
LDL cholesterol level, and the 150-mg dose resulted in a significantly lower incidence of recurrent cardiovascular events than placebo.
Supported by Novartis.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
This article is dedicated to the memory of Arthur Eisner.
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